Heterozygosity for E292V in ABCA3, lung function and COPD in 64,000 individuals

Area of Science:

• Pulmonary Medicine
• Genetics
• Respiratory Diseases

Background:

• Mutations in ATP-binding-cassette-member A3 (ABCA3) are linked to severe neonatal and childhood lung disease.
• The prevalence of chronic lung disease associated with ABCA3 mutations in the general population remains largely unknown.
• This study investigated the hypothesis that heterozygous ABCA3 mutations reduce lung function and increase COPD risk.

Purpose of the Study:

• To determine the clinical significance of ABCA3 mutations in the general population.
• To assess the association between heterozygous ABCA3 mutations and reduced lung function.
• To evaluate the risk of developing chronic obstructive pulmonary disease (COPD) in carriers of ABCA3 mutations.

Main Methods:

• Screening of 760 individuals with extreme pulmonary phenotypes identified novel and known ABCA3 mutations.
• Genotyping of 10,604 individuals from the Copenhagen City Heart Study.
• Validation through genotyping of 54,395 individuals from the Copenhagen General Population Study.

Main Results:

• In the Copenhagen City Heart Study, E292V heterozygotes showed a 5% reduction in FEV1 % predicted and an increased odds ratio for COPD (1.9).
• The A1086D mutation was linked to increased FEV1 % predicted, while other mutations showed no significant association.
• In the combined and larger general population studies, E292V heterozygotes did not exhibit reduced lung function or increased COPD risk.

Conclusions:

• Partially reduced ABCA3 activity due to the E292V mutation is not a major risk factor for reduced lung function or COPD in the general population.
• This finding is significant given that 1.3% of the Danish population carries the E292V mutation.
• The study highlights the importance of population-specific genetic risk assessment for respiratory diseases.